The Valley Desk

NCT03145181 · Interventional trial

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Overall registry status Active not recruiting

Phase 1

Conditions Hematological Malignancies

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov